4.7 Article

Original Research Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study

Journal

EUROPEAN JOURNAL OF CANCER
Volume 164, Issue -, Pages 70-79

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2021.12.031

Keywords

Metastatic breast cancer; Invasive lobular carcinoma; Invasive ductal carcinoma; Overall survival

Categories

Funding

  1. Roche
  2. Pfizer
  3. AstraZeneca
  4. MSD
  5. Eisai
  6. DaiichiSankyo
  7. Roche
  8. Pfizer
  9. AstraZeneca
  10. MSD
  11. Eisai
  12. Daiichi Sankyo

Ask authors/readers for more resources

The histological lobular subtype has an impact on the overall survival of patients with metastatic breast cancer. Lobular histology could be considered as a specific entity that requires tailored management. Further studies are needed to determine the management strategies for these patients.
Background: The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. Patients and methods: Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first line progression-free survival (PFS1) and describe patients and tumour characteristics. Results: Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20-1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07-1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64-0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08-1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67-1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptorpositive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. Conclusion: Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients. 2022 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available